Assessing breast cancer cell lines as tumour models by comparison of mRNA expression profiles.

Abstract:

INTRODUCTION:Breast cancer researchers use cell lines to model myriad phenomena ranging from DNA repair to cancer stem cell phenotypes. Though appropriate, and even requisite, for many studies, the suitability of cell lines as tumour models has come into question owing to possibilities of tissue culture artefacts and clonal selection. These issues are compounded by the inability of cancer cells grown in isolation to fully model the in situ tumour environment, which also contains a plethora of non-tumour cell types. It is thus important to understand similarities and differences between cancer cell lines and the tumours that they represent so that the optimal tumour models can be chosen to answer specific research questions. METHODS:In the present study, we compared the RNA-sequencing transcriptomes of a collection of breast cancer cell lines to transcriptomes obtained from hundreds of tumours using The Cancer Genome Atlas. Tumour purity was accounted for by analysis of stromal and immune scores using the ESTIMATE algorithm so that differences likely resulting from non-tumour cells could be accounted for. RESULTS:We found the transcriptional characteristics of breast cancer cell lines to mirror those of the tumours. We identified basal and luminal cell lines that are most transcriptionally similar to their respective breast tumours. Our comparison of expression profiles revealed pronounced differences between breast cancer cell lines and tumours, which could largely be attributed to the absence of stromal and immune components in cell culture. A focus on the Wnt pathway revealed the transcriptional downregulation or absence of several secreted Wnt antagonists in culture. Gene set enrichment analysis suggests that cancer cell lines have enhanced proliferation and glycolysis independent of stromal and immune contributions compared with breast cancer cells in situ. CONCLUSIONS:This study demonstrates that many of the differences between breast cancer cell lines and tumours are due to the absence of stromal and immune components in vitro. Hence, extra precautions should be taken when modelling extracellular proteins in vitro. The specific differences discovered emphasize the importance of choosing an appropriate model for each research question.

journal_name

Breast Cancer Res

authors

Vincent KM,Findlay SD,Postovit LM

doi

10.1186/s13058-015-0613-0

subject

Has Abstract

pub_date

2015-08-20 00:00:00

pages

114

eissn

1465-5411

issn

1465-542X

pii

10.1186/s13058-015-0613-0

journal_volume

17

pub_type

杂志文章
  • Breast cancer in association with thyroid disorders.

    abstract:BACKGROUND:The relationship between breast cancer and thyroid diseases is controversial. Discrepant results have been reported in the literature. The incidences of autoimmune and nonautoimmune thyroid diseases were investigated in patients with breast cancer and age-matched control individuals without breast or thyroid...

    journal_title:Breast cancer research : BCR

    pub_type: 杂志文章

    doi:10.1186/bcr609

    authors: Turken O,NarIn Y,DemIrbas S,Onde ME,Sayan O,KandemIr EG,YaylacI M,Ozturk A

    更新日期:2003-01-01 00:00:00

  • An investigation of soy intake and mammographic characteristics in Hawaii.

    abstract::This cross-sectional investigation in Hawaii explored the relation between soy foods and mammographic characteristics using two food frequency questionnaires and a computer-assisted density assessment method. Japanese and Chinese women reported significantly greater soy food intake than Caucasian women. Whereas soy in...

    journal_title:Breast cancer research : BCR

    pub_type: 杂志文章

    doi:10.1186/bcr285

    authors: Maskarinec G,Meng L

    更新日期:2001-01-01 00:00:00

  • Treating breast cancer through novel inhibitors of the phosphatidylinositol 3'-kinase pathway.

    abstract::Recent studies indicate that constitutive signaling through the phosphatidylinositol 3'-kinase (PI3K) pathway is a cause of treatment resistance in breast cancer patients. This implies that patients with tumors that exhibit aberrant PI3K signaling may benefit from targeted pathway inhibitors. The first agents to make ...

    journal_title:Breast cancer research : BCR

    pub_type: 评论,杂志文章

    doi:10.1186/bcr1307

    authors: Crowder RJ,Ellis MJ

    更新日期:2005-01-01 00:00:00

  • Preclinical modeling of combined phosphatidylinositol-3-kinase inhibition with endocrine therapy for estrogen receptor-positive breast cancer.

    abstract:INTRODUCTION:Inhibition of phosphatidylinositol-3-kinase (PI3K) induces apoptosis when combined with estrogen deprivation in estrogen receptor (ER)-positive breast cancer. The aims of the present study were to identify effective PI3K pathway inhibitor and endocrine therapy combinations, to evaluate the effect of PI3K p...

    journal_title:Breast cancer research : BCR

    pub_type: 杂志文章

    doi:10.1186/bcr2833

    authors: Sanchez CG,Ma CX,Crowder RJ,Guintoli T,Phommaly C,Gao F,Lin L,Ellis MJ

    更新日期:2011-03-01 00:00:00

  • Initiating breast cancer by PIK3CA mutation.

    abstract::PIK3CA mutations confer constitutive activation of PI3K, which initiates intracellular kinase signaling cascades that promote cell proliferation and survival. Recent studies by Meyer and colleagues, and Liu and colleagues demonstrate that expression of the H1047R exon 20 mutant of PIK3CA in luminal mammary epithelial ...

    journal_title:Breast cancer research : BCR

    pub_type: 杂志文章

    doi:10.1186/bcr3103

    authors: Miller TW

    更新日期:2012-02-07 00:00:00

  • Gene products of chromosome 11q and their association with CCND1 gene amplification and tamoxifen resistance in premenopausal breast cancer.

    abstract:INTRODUCTION:The amplification event occurring at chromosome locus 11q13, reported in several different cancers, includes a number of potential oncogenes. We have previously reported amplification of one such oncogene, namely CCND1, to be correlated with an adverse effect of tamoxifen in premenopausal breast cancer pat...

    journal_title:Breast cancer research : BCR

    pub_type: 杂志文章

    doi:10.1186/bcr2150

    authors: Lundgren K,Holm K,Nordenskjöld B,Borg A,Landberg G

    更新日期:2008-01-01 00:00:00

  • Role of ADAM17 in the non-cell autonomous effects of oncogene-induced senescence.

    abstract:INTRODUCTION:Cellular senescence is a terminal cell proliferation arrest that can be triggered by oncogenes. One of the traits of oncogene-induced senescence (OIS) is the so-called senescence-associated secretory phenotype or senescence secretome. Depending on the context, the non-cell autonomous effects of OIS may var...

    journal_title:Breast cancer research : BCR

    pub_type: 杂志文章

    doi:10.1186/s13058-015-0619-7

    authors: Morancho B,Martínez-Barriocanal Á,Villanueva J,Arribas J

    更新日期:2015-08-12 00:00:00

  • Tyrosine kinase signalling in breast cancer: modulation of tyrosine kinase signalling in human breast cancer through altered expression of signalling intermediates.

    abstract::The past decade has seen the definition of key signalling pathways downstream of receptor tyrosine kinases (RTKs) in terms of their components and the protein-protein interactions that facilitate signal transduction. Given the strong evidence that links signalling by certain families of RTKs to the progression of brea...

    journal_title:Breast cancer research : BCR

    pub_type: 杂志文章,评审

    doi:10.1186/bcr54

    authors: Kairouz R,Daly RJ

    更新日期:2000-01-01 00:00:00

  • Comparison of percent density from raw and processed full-field digital mammography data.

    abstract:INTRODUCTION:Mammographic density has been established as a strong risk factor for breast cancer, primarily using digitized film mammograms. Full-field digital mammography (FFDM) is replacing film mammography, has different properties than film, and provides both raw and processed clinical display representation images...

    journal_title:Breast cancer research : BCR

    pub_type: 杂志文章

    doi:10.1186/bcr3372

    authors: Vachon CM,Fowler EE,Tiffenberg G,Scott CG,Pankratz VS,Sellers TA,Heine JJ

    更新日期:2013-01-04 00:00:00

  • Whither high-dose chemotherapy in breast cancer?

    abstract::Four trials of high-dose chemotherapy with stem cell support in breast cancer in the adjuvant and metastatic settings have shown no long-term disease-free or overall survival gain. This relative failure of a single high-dose therapy we believe opens up the development of a dose-dense approach with block scheduling as ...

    journal_title:Breast cancer research : BCR

    pub_type: 杂志文章,评审

    doi:10.1186/bcr262

    authors: Mayer A,Earl H

    更新日期:2001-01-01 00:00:00

  • Combined the SMAC mimetic and BCL2 inhibitor sensitizes neoadjuvant chemotherapy by targeting necrosome complexes in tyrosine aminoacyl-tRNA synthase-positive breast cancer.

    abstract:BACKGROUND:Chemotherapy is the standard treatment for breast cancer; however, the response to chemotherapy is disappointingly low. Here, we investigated the alternative therapeutic efficacy of novel combination treatment with necroptosis-inducing small molecules to overcome chemotherapeutic resistance in tyrosine amino...

    journal_title:Breast cancer research : BCR

    pub_type: 杂志文章

    doi:10.1186/s13058-020-01367-7

    authors: Lee KM,Lee H,Han D,Moon WK,Kim K,Oh HJ,Choi J,Hwang EH,Kang SE,Im SA,Lee KH,Ryu HS

    更新日期:2020-11-25 00:00:00

  • Progestin effects on cell proliferation pathways in the postmenopausal mammary gland.

    abstract:INTRODUCTION:Menopausal hormone therapies vary widely in their effects on breast cancer risk, and the mechanisms underlying these differences are unclear. The primary goals of this study were to characterize the mammary gland transcriptional profile of estrogen + progestin therapy in comparison with estrogen-alone or t...

    journal_title:Breast cancer research : BCR

    pub_type: 杂志文章

    doi:10.1186/bcr3456

    authors: Wood CE,Branstetter D,Jacob AP,Cline JM,Register TC,Rohrbach K,Huang LY,Borgerink H,Dougall WC

    更新日期:2013-01-01 00:00:00

  • A migrant study of pubertal timing and tempo in British-Bangladeshi girls at varying risk for breast cancer.

    abstract:INTRODUCTION:Earlier menarche is related to subsequent breast cancer risk, yet international differences in the age and tempo of other pubertal milestones and their relationships with body mass index (BMI) are not firmly established in populations at differing risk for breast cancer. We compared age and tempo of adrena...

    journal_title:Breast cancer research : BCR

    pub_type: 杂志文章

    doi:10.1186/s13058-014-0469-8

    authors: Houghton LC,Cooper GD,Bentley GR,Booth M,Chowdhury OA,Troisi R,Ziegler RG,Hoover RN,Katki HA

    更新日期:2014-11-15 00:00:00

  • DACT1, an antagonist to Wnt/β-catenin signaling, suppresses tumor cell growth and is frequently silenced in breast cancer.

    abstract:INTRODUCTION:Aberrant activation of Wnt/β-catenin signaling plays an important role in the pathogenesis of breast cancer. DACT1 (Dapper/Frodo) has been identified as involved in antagonizing Wnt/β-catenin signaling through interacting with Dishevelled (Dvl), a central mediator of Wnt signaling, whereas its role in brea...

    journal_title:Breast cancer research : BCR

    pub_type: 杂志文章

    doi:10.1186/bcr3399

    authors: Yin X,Xiang T,Li L,Su X,Shu X,Luo X,Huang J,Yuan Y,Peng W,Oberst M,Kelly K,Ren G,Tao Q

    更新日期:2013-03-12 00:00:00

  • Derlin-1 is overexpressed in human breast carcinoma and protects cancer cells from endoplasmic reticulum stress-induced apoptosis.

    abstract:INTRODUCTION:Aberrant microenvironment and endoplasmic reticulum (ER) stress are associated with solid-tumor progression. Stress proteins, like heat shock proteins and glucose-regulated proteins, are frequently overexpressed in human tumors. It has been reported that derlin-1 is involved in ER stress response. In vitro...

    journal_title:Breast cancer research : BCR

    pub_type: 杂志文章

    doi:10.1186/bcr1849

    authors: Wang J,Hua H,Ran Y,Zhang H,Liu W,Yang Z,Jiang Y

    更新日期:2008-01-01 00:00:00

  • Increased genomic burden of germline copy number variants is associated with early onset breast cancer: Australian breast cancer family registry.

    abstract:BACKGROUND:Women with breast cancer who have multiple affected relatives are more likely to have inherited genetic risk factors for the disease. All the currently known genetic risk factors for breast cancer account for less than half of the average familial risk. Furthermore, the genetic factor(s) underlying an increa...

    journal_title:Breast cancer research : BCR

    pub_type: 杂志文章

    doi:10.1186/s13058-017-0825-6

    authors: Walker LC,Pearson JF,Wiggins GA,Giles GG,Hopper JL,Southey MC

    更新日期:2017-03-16 00:00:00

  • Chromogenic in situ hybridisation for the assessment of HER2 status in breast cancer: an international validation ring study.

    abstract:INTRODUCTION:Before any new methodology can be introduced into the routine diagnostic setting it must be technically validated against the established standards. To this end, a ring study involving five international pathology laboratories was initiated to validate chromogenic in situ hybridisation (CISH) against fluor...

    journal_title:Breast cancer research : BCR

    pub_type: 杂志文章,多中心研究

    doi:10.1186/bcr1776

    authors: van de Vijver M,Bilous M,Hanna W,Hofmann M,Kristel P,Penault-Llorca F,Rüschoff J

    更新日期:2007-01-01 00:00:00

  • Inheritance of deleterious mutations at both BRCA1 and BRCA2 in an international sample of 32,295 women.

    abstract:BACKGROUND:Most BRCA1 or BRCA2 mutation carriers have inherited a single (heterozygous) mutation. Transheterozygotes (TH) who have inherited deleterious mutations in both BRCA1 and BRCA2 are rare, and the consequences of transheterozygosity are poorly understood. METHODS:From 32,295 female BRCA1/2 mutation carriers, w...

    journal_title:Breast cancer research : BCR

    pub_type: 杂志文章,多中心研究

    doi:10.1186/s13058-016-0768-3

    authors: Rebbeck TR,Friebel TM,Mitra N,Wan F,Chen S,Andrulis IL,Apostolou P,Arnold N,Arun BK,Barrowdale D,Benitez J,Berger R,Berthet P,Borg A,Buys SS,Caldes T,Carter J,Chiquette J,Claes KB,Couch FJ,Cybulski C,Daly MB,d

    更新日期:2016-11-11 00:00:00

  • Clinical outcomes after palbociclib with or without endocrine therapy in postmenopausal women with hormone receptor positive and HER2-negative metastatic breast cancer enrolled in the TREnd trial.

    abstract::Currently, there is limited data regarding the effectiveness of standard subsequent line therapies such as endocrine therapy, chemotherapy, or targeted agents after progression on CDK4/6 inhibitor-based regimens. This paper describes time-to-treatment failure beyond progression on palbociclib or palbociclib+endocrine ...

    journal_title:Breast cancer research : BCR

    pub_type: 杂志文章

    doi:10.1186/s13058-019-1149-5

    authors: Rossi L,Biagioni C,McCartney A,Migliaccio I,Curigliano G,Sanna G,Moretti E,Minisini AM,Cinieri S,Tondini C,Arpino G,Bernardo A,Martignetti A,Risi E,Pestrin M,Boni L,Benelli M,Biganzoli L,Di Leo A,Malorni L

    更新日期:2019-05-29 00:00:00

  • PIK3CA mutations in breast cancer: reconciling findings from preclinical and clinical data.

    abstract::PIK3CA mutations represent one of the most common genetic aberrations in breast cancer. They have been reported to be present in over one-third of cases, with enrichment in the luminal and in human epidermal growth factor receptor 2-positive subtypes. Substantial preclinical data on the oncogenic properties of these m...

    journal_title:Breast cancer research : BCR

    pub_type: 杂志文章,评审

    doi:10.1186/bcr3605

    authors: Zardavas D,Phillips WA,Loi S

    更新日期:2014-01-23 00:00:00

  • 17-allyamino-17-demethoxygeldanamycin treatment results in a magnetic resonance spectroscopy-detectable elevation in choline-containing metabolites associated with increased expression of choline transporter SLC44A1 and phospholipase A2.

    abstract:INTRODUCTION:17-allyamino-17-demethoxygeldanamycin (17-AAG), a small molecule inhibitor of Hsp90, is currently in clinical trials in breast cancer. However, 17-AAG treatment often results in inhibition of tumor growth rather than shrinkage, making detection of response a challenge. Magnetic resonance spectroscopy (MRS)...

    journal_title:Breast cancer research : BCR

    pub_type: 杂志文章

    doi:10.1186/bcr2729

    authors: Brandes AH,Ward CS,Ronen SM

    更新日期:2010-01-01 00:00:00

  • The functional loss of the retinoblastoma tumour suppressor is a common event in basal-like and luminal B breast carcinomas.

    abstract:INTRODUCTION:Breast cancers can be classified using whole genome expression into distinct subtypes that show differences in prognosis. One of these groups, the basal-like subtype, is poorly differentiated, highly metastatic, genomically unstable, and contains specific genetic alterations such as the loss of tumour prot...

    journal_title:Breast cancer research : BCR

    pub_type: 杂志文章

    doi:10.1186/bcr2142

    authors: Herschkowitz JI,He X,Fan C,Perou CM

    更新日期:2008-01-01 00:00:00

  • Imprint of parity and age at first pregnancy on the genomic landscape of subsequent breast cancer.

    abstract:BACKGROUND:Although parity and age at first pregnancy are among the most known extrinsic factors that modulate breast cancer risk, their impact on the biology of subsequent breast cancer has never been explored in depth. Recent data suggest that pregnancy-induced tumor protection is different according to breast cancer...

    journal_title:Breast cancer research : BCR

    pub_type: 杂志文章

    doi:10.1186/s13058-019-1111-6

    authors: Nguyen B,Venet D,Lambertini M,Desmedt C,Salgado R,Horlings HM,Rothé F,Sotiriou C

    更新日期:2019-02-15 00:00:00

  • The seventh ENBDC workshop on methods in mammary gland development and cancer.

    abstract::The seventh annual meeting of the European Network of Breast Development and Cancer Laboratories, held in Weggis, Switzerland, in April 2015, was focused on techniques for the study of normal and cancer stem cells, cell fate decisions, cancer initiation and progression. ...

    journal_title:Breast cancer research : BCR

    pub_type: 杂志文章

    doi:10.1186/s13058-015-0629-5

    authors: Glukhova MA,Hynes N,Vivanco Md,van Amerongen R,Clarke RB,Bentires-Alj M

    更新日期:2015-09-02 00:00:00

  • Metastatic breast cancer cells inhibit osteoblast differentiation through the Runx2/CBFβ-dependent expression of the Wnt antagonist, sclerostin.

    abstract:INTRODUCTION:Breast cancers frequently metastasise to the skeleton where they cause osteolytic bone destruction by stimulating osteoclasts to resorb bone and by preventing osteoblasts from producing new bone. The Runt-related transcription factor 2, Runx2, is an important determinant of bone metastasis in breast cancer...

    journal_title:Breast cancer research : BCR

    pub_type: 杂志文章

    doi:10.1186/bcr3048

    authors: Mendoza-Villanueva D,Zeef L,Shore P

    更新日期:2011-10-27 00:00:00

  • CYP17 5'-UTR MspA1 polymorphism and the risk of premenopausal breast cancer in a German population-based case-control study.

    abstract:INTRODUCTION:Studies on the association between the cytochrome P450c17alpha gene (CYP17) 5'-untranslated region MspA1 genetic polymorphism and breast cancer risk have yielded inconsistent results. Higher levels of estrogen have been reported among young nulliparous women with the A2 allele. Therefore we assessed the im...

    journal_title:Breast cancer research : BCR

    pub_type: 杂志文章

    doi:10.1186/bcr1027

    authors: Verla-Tebit E,Wang-Gohrke S,Chang-Claude J

    更新日期:2005-01-01 00:00:00

  • Redefining prognostic factors for breast cancer: YB-1 is a stronger predictor of relapse and disease-specific survival than estrogen receptor or HER-2 across all tumor subtypes.

    abstract:INTRODUCTION:Gene expression analysis is used to subtype breast cancers such that the most aggressive tumors are identified, but translating this into clinical practice can be cumbersome. Our goal is to develop a universal biomarker that distinguishes patients at high risk across all breast cancer subtypes. We previous...

    journal_title:Breast cancer research : BCR

    pub_type: 杂志文章

    doi:10.1186/bcr2156

    authors: Habibi G,Leung S,Law JH,Gelmon K,Masoudi H,Turbin D,Pollak M,Nielsen TO,Huntsman D,Dunn SE

    更新日期:2008-01-01 00:00:00

  • Analysis of EpCAM positive cells isolated from sentinel lymph nodes of breast cancer patients identifies subpopulations of cells with distinct transcription profiles.

    abstract:INTRODUCTION:The presence of tumor cells in the axillary lymph nodes is the most important prognostic factor in early stage breast cancer. However, the optimal method for sentinel lymph node (SLN) examination is still sought and currently many different protocols are employed. To examine two approaches for tumor cell d...

    journal_title:Breast cancer research : BCR

    pub_type: 杂志文章

    doi:10.1186/bcr2922

    authors: Tveito S,Andersen K,Kåresen R,Fodstad Ø

    更新日期:2011-08-04 00:00:00

  • Fatal attraction: why breast cancer cells home to bone.

    abstract::Osteolytic metastases due to breast cancer are serious events. The interactions between breast cancer cells with the microenvironment of bone have been thought to provide an ideal milieu for cancer cells. Recent data now indicate that migration of breast cancer cells into bone and their subsequent growth into metastas...

    journal_title:Breast cancer research : BCR

    pub_type: 社论

    doi:10.1186/bcr1848

    authors: Hofbauer LC,Rachner T,Singh SK

    更新日期:2008-01-01 00:00:00

  • New generation breast cancer cell lines developed from patient-derived xenografts.

    abstract:BACKGROUND:Breast cancer is a highly heterogeneous disease characterized by multiple histologic and molecular subtypes. While a myriad of breast cancer cell lines have been developed over the past 60 years, estrogen receptor alpha (ER)+ disease and some mutations associated with this subtype remain underrepresented. He...

    journal_title:Breast cancer research : BCR

    pub_type: 杂志文章

    doi:10.1186/s13058-020-01300-y

    authors: Finlay-Schultz J,Jacobsen BM,Riley D,Paul KV,Turner S,Ferreira-Gonzalez A,Harrell JC,Kabos P,Sartorius CA

    更新日期:2020-06-23 00:00:00